Abstract
Introduction: Clinically important deterioration (CID) in COPD is a measure of meaningful short-term worsening in lung function, health status or a first acute exacerbation. The economic and quality of life (QoL) impact of avoiding CID is unclear. This analysis of data from the 3-year TOwards a Revolution in COPD Health (TORCH) study examined this question.
Methods: This post hoc analysis of TORCH (NCT00268216) compared annual costs and QoL in unstable patients with any CID (CID+) vs stable CID-free patients (CID-). CID+ status in any treatment arm in the first 6 months was defined as: ≥100 mL decline in FEV1 or ≥4-unit deterioration in SGRQ total score from baseline or a first moderate/severe exacerbation. Costs were calculated based on healthcare resource use captured from 6 months to study end, applying UK NHS unit costs. QoL was measured using the EQ-5D utility index. Adjusted values, controlled for baseline characteristics, treatment assignment and CID status, are presented.
Results: Following study completion, 3769 and 1989 patients contributed to the 3-year cost and QoL analysis, respectively. Significantly lower annual costs/patient and higher utility scores were seen for CID- vs CID+ patients (Figure).
Conclusions: Maintaining COPD stability and avoiding short-term CID may be associated with year-on-year cost savings and better preservation of QoL.
Funding: GSK (HO-16-16345)
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, OA1660.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018
